Introduction {#s1}
============

Ensuring safety, efficacy, and quality of medicines for the pediatric population is a challenge because data on many medicines are scarce due to the lack of clinical trials involving children ([@B28]). As a result, children may be exposed to age-inappropriate medicines that can lead to increased incidence of Adverse Drug Reactions (ADRs) ([@B5]). Risk factors associated with ADRs in children include polypharmacy, age, off-label (OL) use, and unlicensed (UL) use ([@B5]; [@B30]).

Reports of ADRs screening from surveillance systems may offer information about a different drug‐event combination (or pairs) by the mining of a large volume of data ([@B25]). Such safety signals---a potentially causal association or a new aspect of a known association between an intervention and a set of related events---may be critical for drug regulation and improvements in child health ([@B15]; [@B37]).

Electronic data use for children's safety is increasing, especially in North America and Europe ([@B7]). ADR prevalence may vary due to differences in pharmacovigilance and polypharmacy management among low and middle-income countries ([@B35]; [@B3]). In Brazil, the first exclusive investigation about children from the Brazilian database (*Notivisa*) assessed 3,330 spontaneous reports of suspected ADRs and showed approximately 60% were classified as serious events ([@B29]). This new study aimed to analyze deaths and other serious ADR reports and to identify safety signals in children.

Materials and Methods {#s2}
=====================

We carried out a cross-sectional study of children with suspected SADRs notified on the *Notivisa*, created in 2008. *Notivisa* is a computerized system developed by the National Health Surveillance Agency (*Anvisa*) to receive notifications of incidents, adverse events, and technical complaints related to the use of health products and medicines by manufacturers, users, health professionals, and health services---mainly those within the Sentinel Network observatory.

The Sentinel Network is an observatory constituting around 200 (general and specialized) accredited hospitals and other health services for monitoring and reporting adverse drug events. Sentinel functions include strategies for surveillance of ADRs and precise mechanisms for identification and investigation, dissemination of results, mandatory risk minimization plans and integration of other institutions for network hospitals. Training for this network was carried out by Anvisa, and it considers the elements described above, including the seriousness and causality assessment of ADRs. SADRs are investigated in health services by patient safety teams before being reported to *Notivisa* ([@B9]; [@B10]; [@B43]; [@B33]; [@B12]).

*Anvisa* supplied data on *Notivisa* website reports as a Microsoft Excel^®^ file for the first years of reporting system consolidation, and only complete data between 2008 to 2013 were available for analysis.

Data on suspected ADRs in children (0-12 years old) were identified and selected by age information on the date of the adverse event or the calculation of the difference between the date of onset event and the patient's birth date. There were no linkage processes with other databases.

The events were described according to the WHO Adverse Reaction Terminology (WHO-ART) and classified following the International Conference on Harmonisation guidance ([@B14]; [@B26]; [@B47]) on the *Notivisa* database as serious outcomes (i) death; life-threatening; hospitalization; disability (significant or persistent); congenital anomaly, medically important events, and (ii) not serious. All reports classified as 'not serious' were excluded.

Information about all suspected drugs reported, including pharmaceutical form and administration route, were collected and encoded using the Anatomic Therapeutic Chemical (ATC) classification system (1^st^ and 5^th^ level). OL use in children was verified from the Brazilian labels (summary of product characteristics) of each drug (approved by Anvisa). Drugs not approved for use by the children's age group were classified as OL use, and drugs not licensed in Brazil were classified as UL ([@B22]; [@B4]). Age group classification was based on the pediatric stage of development ([@B2]).

Disproportionality analysis of ADR reporting was used to identify signals of disproportionate reporting (SDR). SDR refers to statistical associations between drugs and adverse events. The disproportionality analysis method recommended by the European Medicines Agency, namely Reporting Odds Ratio (ROR) and thresholds, is based on its 95% confidence interval and the number of individual cases ([@B19]). ROR measure is defined by the formula \[(a.d)/(c.b)\], based on a two-dimensional contingency table where value "a" indicates the number of individual cases that list the target drug P and the target ADR R; value "b" indicates the number of individual cases that list the target drug P but not the target ADR R; value "c" indicates the number of individual cases that list the target ADR R but not the target drug P, and value "d" indicates the number of individual cases that do not list the target ADR R or the target drug P. They should be distinguished from signals that can originate from individual case analysis and epidemiological studies. This method assumes that when a signal (involving a particular adverse event) is identified for a drug, this adverse event is reported relatively more frequently in association with this drug than with other drugs ([@B18]).

We adopted the following criteria to define a SDR ([@B19]): number of individual cases is greater than or equal to 3 for active substances contained in medicinal products included in an additional monitoring list defined by the EMA; number of individual cases is greater than or equal to 5 for the other active substances and event belongs to the important medical event terms list. ROR calculations were performed for all drugs with a ≥ 3. Nevertheless, we differentiate between the cases where 3 ≤ a \< 5 and a ≥ 5. A situation occurs when c=0, or when all database reports containing a target ADR are associated with only one drug. In this case, ROR cannot be computed. ROR value is arbitrarily set at 99.9 to reflect the presence of a possible SDR.

Other analyses were conducted using SPSS version 22.0 for Windows (IBM Corporation, USA). The chi-square test with a significance level of 5% was used to assess the association between the seriousness of ADR, age group, and the number of drugs prescribed as OL.

The use of *Notivisa* data was formally authorized by *Anvisa*. This study was approved by the Hospital Universitário Clementino Fraga Filho Ethics Committee (registration number 931.400).

Results {#s3}
=======

General Findings {#s3_1}
----------------

One-thousand-nine-hundred-and-seventy-seven SADRs were assessed, and almost 30% involved 0-1-year-olds. The frequency of serious events was significantly different between pediatric age groups (p \< 0.05) ([**Table 1**](#T1){ref-type="table"}). SADRs were more common in boys (54%) than in girls. However, 1% of the total reports of suspected SADRs did not include a specification of gender. More than 70% of reports were done from hospitals, mainly from the Sentinel Network, by patient safety teams. Approximately 28% of suspected SADRs were associated with death, were life-threatening, and caused prolonged hospitalization ([**Table 1**](#T1){ref-type="table"}).

###### 

Distribution of SADR reports (n=1977) by patient age in Brazil between 2008-2013.

  Seriousness                                Baby (aged 0 -- 1 y)   Toddler(aged 1 - 3 y)   Preschool(aged 3 - 5 y)   Primary school (aged 5 - 8 y)   Secondary school (aged 8 - 12 y)   Total (%)
  ------------------------------------------ ---------------------- ----------------------- ------------------------- ------------------------------- ---------------------------------- -------------
  1 -- Death                                 24                     14                      10                        13                              14                                 75 (4,0)
  2 - Life threatening                       102                    36                      26                        19                              33                                 216 (11,0)
  3 - Prolonged hospitalization              65                     61                      44                        28                              65                                 263 (13,0)
  4 - Congenital abnormalities               2                      1                       0                         0                               0                                  3 (0,2)
  5 - Persistent or significant disability   4                      3                       9                         4                               7                                  27 (1,3)
  6 - Medically important events             345                    230                     192                       203                             423                                1393 (70,5)
  **Total**                                  **542**                **345**                 **281**                   **267**                         **542**                            **1977**

SADR, Serious Adverse Drug Reaction; y = year(s). Congenital abnormalities: SADR in children related to medicine use during the mother's pregnancy. Source: Notivisa/Anvisa. P value \< 0,001 (Chi Square test).

Two-thousand-two-hundred-and-twenty-nine drugs were identified as being associated with reports of SADRs (mean: 1.1 drugs by report; range from 1 to 6). Anti-infectives for systemic use (n = 1048; 47%), drugs for the nervous system, including non-steroidal anti-inflammatory drugs, (n=384; 17.2%) and antineoplastic, and immunomodulating agents (n=221; 10%) were most commonly involved in suspected SADRs ([**Table 2**](#T2){ref-type="table"}).

###### 

Distribution of suspected drugs by ATC classification involved in 1977 reports of SADRs in Brazil between 2008-2013.

  Description                                               Frequency   
  --------------------------------------------------------- ----------- ------
  **Drug class (ATC)**                                      **2229**    100
  Alimentary tract and metabolism (A)                       153         6,9
  Blood and blood forming organs (B)                        100         4,5
  Cardiovascular system (C)                                 54          2,4
  Dermatological (D)                                        9           0,4
  Genito urinary system and sex hormones (G)                2           0,1
  Systemic hormonal preparations (H)                        56          2,5
  Anti-infectives for systemic use (J)                      1048        47,0
  Antineoplastic and immunomodulating agents (L)            221         10,0
  Musculo-skeletal system (M)                               51          2,3
  Nervous system (N)                                        384         17,2
  Antiparasitic products, insecticides and repellents (P)   24          1,0
  Respiratory system (R)                                    47          2,1
  Sensory organs (S)                                        43          1,9
  Various (V)                                               37          1,7

ATC, Anatomical Therapeutic Chemical Code; SADR, Serious Adverse Drug Reactions. Source: Notivisa/Anvisa.

Intravenous powder or solutions were the main pharmaceutical forms reported (69%), followed by tablets (9,3%), oral solutions (4,5%), and oral suspensions (3,7%). Administration route and pharmaceutical form was indeterminate in 9,6% of reports.

Twenty-five percent (n=564) of drugs present in suspected SADRs reports involved OL use by age, according to the Brazilian label, and less than 1% (n=11) of cases were classified as UL use. The frequency of OL prescriptions was significantly higher in events reported, such as persistent disability, prolonged hospitalization, and death (p\<0.05) ([**Table 3**](#T3){ref-type="table"}).

###### 

Distribution of suspected drugs (total and OL prescription by age) by seriousness of SADR in children in Brazil between 2008-2013.

  Seriousness classification             Number of drugs                   
  -------------------------------------- ----------------- --------------- ---------
  Death                                  89                26 (29%)        0.043\*
  Life threatening                       239               50 (21%)        
  Prolonged hospitalization              306               89 (29%)        
  Congenital abnormalities               3                 2 (67%)         
  Persistent or significant disability   31                12 (39%)        
  Medically important events             1561              385 (25%)       
  **Total**                              **2229**          **564 (25%)**   

OL, Off-label; SADR, Serious Adverse Drug Reaction. Values in parenthesis are percentages. \*Statistically significant at level of P \< 0.05 (Chi Square test).

Deaths {#s3_2}
------

There were 75 deaths involving 89 suspected drugs. The majority of deaths were related to either cardiovascular events (22%), respiratory disorders (19%), or general disorders (23%). Sixty-seven percent of these fatal events were not described on Brazilian labels.

Three ATC groups concentrated the major part of suspected drugs: alimentary tract and metabolism (n=26; 29%), antineoplastic (n=19; 22%), and anti-infectives (n=18; 20%). Miglustat and imipenem/cilastatin showed 88% and 25% of OL age use, respectively. Drug indication, as represented by ICD (International Classification of Diseases) classification, showed the predominance of metabolic disorders and infections. These findings are presented in [**Table 4**](#T4){ref-type="table"}.

###### 

Description of suspected drugs (from main ATC groups reported) involved in child deaths on Notivisa between 2008-2013.

  Suspected Drug                                       ICD Classification (drug indication)                                                                                                                       Total reports by drugs (n)/OL or UL\* use (n)   Main events^1^ classified by System Organ Class
  ---------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  **A - Alimentary tract and metabolism**                                                                                                                                                                         **26 (12)**                                     
  Alfaglicosidase                                      Glycogen storage disease                                                                                                                                   3 (0)                                           Cardiovascular/Respiratory
  Calcium gluconate                                    Not reported                                                                                                                                               1 (0)                                           General disorders
  Imiglucerase                                         Lipid deposit disorders                                                                                                                                    3 (0)                                           General disorders/Respiratory
  Laronidase                                           Mucopolysaccharidosis type I                                                                                                                               6 (0)                                           General disorders/Cardiovascular/Respiratory
  Metoclopramide                                       Nausea and vomiting                                                                                                                                        3 (3)                                           Blood/Cardiovascular
  Miglustat                                            Not reported                                                                                                                                               9 (8)                                           General disorders/Gastro-intestinal system/Neurologic/Respiratory
  Ondansetron                                          Nausea and vomiting                                                                                                                                        1(1)                                            Cardiovascular
  **J - Anti-infectives for systemic use**                                                                                                                                                                        **18 (4)**                                      
  Ampiciline                                           Not reported                                                                                                                                               3 (0)                                           Neurologic
  Benzylpenicillin                                     Not reported                                                                                                                                               1 (0)                                           Neurologic
  Caspofungin                                          Localized infections of the skin and subcutaneous tissue                                                                                                   1 (1)                                           General disorders
  Ceftriaxone                                          Acute upper airway infection                                                                                                                               1 (1)                                           Respiratory
  Imipenem/Cilastatin                                  Complications of heart defects; Bacterial pneumonia; Infections due to other mycobacteria; Other bacterial diseases; Unspecified microorganism pneumonia   8 (2)                                           Blood/General disorders/Cardiovascular/Endocrine/Gastro-intestinal/Musculo-skeletal system/Neurologic/Respiratory system/Urinary
  Imunoglobuline (human)                               Not reported                                                                                                                                               1 (0)                                           Cardiovascular
  Meropenem                                            Not reported                                                                                                                                               1 (0)                                           Neurologic
  Metronidazole                                        Other venous embolism and thrombosis                                                                                                                       1 (0)                                           Blood
  Oxacillin                                            Not reported                                                                                                                                               1 (0)                                           Skin
  **L - Antineoplastic and immunomodulating agents**                                                                                                                                                              **19 (14)**                                     
  Carboplatin                                          Not reported                                                                                                                                               1 (1)                                           General disorders
  Carmustine + Cytarabine + Etoposide + Melphalan      Not reported                                                                                                                                               4 (4)                                           Cardiovascular
  Clofarabine                                          Lymphoid leukemia                                                                                                                                          8 (8)\*                                         Blood/General disorders/Cardiovascular/Respiratory
  Ifosfamide                                           Not reported                                                                                                                                               2 (0)                                           Gastro-intestinal
  Methotrexate                                         Not reported                                                                                                                                               2 (0)                                           Blood/General disorders/Cardiovascular/Gastro-intestinal system/Neurologic/Respiratory/Skin
  Rituximab                                            Adverse effects of primarily systemic action substances                                                                                                    1 (1)                                           Endocrine
  Vincristine                                          Lymphoid leukemia                                                                                                                                          1 (0)                                           General disorders

ATC, Anatomical Therapeutic Chemical Code; ICD, International Classification of Diseases; OL, Off-label; UL\*, Unlicensed use; Not reported, no information about drug indication on database.

Drugs classified in other groups: heparin, bosentan, furosemide, gentamicin, hydrocortisone, methylprednisolone, ibuprofen, metamizole sodium, methadone, alpha poractant, fenoterol, fluticasone and salmeterol, technetium (^99m^tc) ethylenedicysteine, coagulation factor viii, coagulation factor IX, II, VII, and X in combination, were also reported. There were four cases, all involving newborns, related to contamination of solutions (parenteral nutrition and sodium chloride).

Safety Signals {#s3_3}
--------------

Using the disproportionality analysis, applying a signal threshold of (N) ≥3, results pointed to 65 SDRs involving mostly anti-infectives for systemic use (34%), antineoplastic agents (15%), nervous system drugs (12%), and alimentary tract and metabolism drugs (11%). For (N) ≥5, 42 signals were involved mostly with anti-infectives for systemic use (55%), nervous system (17%), antineoplastic agents (12%), and sensory organs drugs (12%). From 107 signals of disproportionate reporting, 16 events (15%) were not described on the Brazilian label, ([**Table 5**](#T5){ref-type="table"}). Two pairs were suspected with deaths: imipenen/cilastatin--pneumonia, and laronidase--respiratory insufficiency.

###### 

Drug-event pairs associated with Signals of Disproportionate Reporting (SDR) not described in drug label (Brazilian label).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Suspected Drug            Event description           ROR     Lower bound 95%                         Seriousness of suspected ADRs found   Thresholds of number of cases (n)
  ------------------------- --------------------------- ------- --------------------------------------- ------------------------------------- -----------------------------------
  Alphaglucosidase          Asthenia                    66.77   27.10                                   Medically important                   ≥5

  Amphotericin B            Hypokalemia                 54.24   24.95                                   Life threatening\                     ≥5
                                                                                                        Prolonged hospitalization\            
                                                                                                        Medically important                   

  Ciclosporin               Nystagmus                   47.11   13.70                                   Medically important events            ≥3

  Psychosis                 15.30                       4.30    Medically important events              ≥3                                    

  Blurred vision            212.5                       37.38   Life threatening\                       ≥3                                    
                                                                Prolonged hospitalization\                                                    
                                                                Persistent or significant disability\                                         
                                                                Medically important                                                           

  Imipenem and Cilastatin   Pneumonia                   42.80   11.68                                   Death                                 ≥3

  Laronidase                Respiratory insufficiency   29.05   7.53                                    Death\                                ≥3
                                                                                                        Prolonged hospitalization             

  Papules                   15.02                       3.70    Medically important                     ≥3                                    

  Metoclopramide            Psychosis                   15.30   54.27                                   Medically important                   ≥3

  Oxacillin                 Cough                       2.94    1.00                                    Life threatening\                     ≥3
                                                                                                        Prolonged hospitalization\            
                                                                                                        Medically important                   

  Tropicamide               Apnea                       75.95   18.33                                   Life threatening\                     ≥3
                                                                                                        Medically important events            

  Asthenia                  33.67                       13.89   ≥5                                                                            

  Bradycardia               33.67                       13.89   ≥5                                                                            

  Persistent crying         677.71                      82.54   ≥5                                                                            

  Dyspnea                   11.11                       4.72    ≥5                                                                            

  Vancomycin                Petechiae                   3.38    1.23                                    Medically important events            ≥5
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ROR, Reporting Odds Ratio; ADR, Adverse Drug Reaction.

Discussion {#s4}
==========

Our study found a higher frequency of SADRs in children (60%) than is generally reported compared to other pediatric studies, in which rates of SADRs reported in national databases ranged from 0% to 66.7% ([@B1]; [@B40]). The relatively high reported frequency of SADRs in children in this study may be due to the high proportion of *Notivisa* data attributed to inpatients. Another hypothesis is that this database does not discriminate the adverse drug reactions caused by medication errors. The Adverse Drug Reactions in Children (ADRIC) program in the UK reported the incidence of ADRs for hospitalized children as 15.9% ([@B41]). A retrospective analysis based on 5 years of pharmacovigilance studies (2012-2016) in an Italian hospital observed 834 ADRs, of which 239 (29%) were serious ([@B30]).

One study reported age as a risk factor for an ADR ([@B30]). Our results suggest evidence of an association (p\<0.05) between age and the seriousness of an ADR ([**Table 1**](#T1){ref-type="table"}).

Vancomycin (n=9,2%), Ceftriaxone (5,9%), and Oxacillin (n=5,7%) were the specific drugs most commonly reported as being associated with a suspected SADR in the current study. Anti-infectives and antiepileptics represent the most frequently reported therapeutic classes associated with ADRs in children admitted to hospital, and non-steroidal anti-inflammatory drugs were often reported as associated with ADRs in outpatient children ([@B40]). Our findings agree with this review, although the proportion of ADRs associated with antiepileptic drugs was small (1%).

The intravenous route represented the most common dosage form (69%) associated with a suspected SADR, which also may be attributable to the Sentinel Network notifications being dominated by inpatients. However, this route represents a higher risk for the incidence of medical errors than with other formulations ([@B24]), which reinforces the necessity of discussions about the selection and development of better formulations for children in Brazil. Furthermore, cases of contamination of sterile solutions have been reported, which may be related to problems in preparing and administering these products for newborns.

The Food and Drug Administration (FDA) and EMA implemented regulatory initiatives for pediatric medicines in the early 2000s. Both agencies created legislation to perform studies in children for products seeking marketing authorization in adults that meet certain criteria based on the relevance to public health ([@B44]). These initiatives have had a positive impact on pediatric drug development, and pediatric considerations have become an integral part of pharmaceutical development across the US and Europe ([@B17]; [@B20]).

In Brazil, even with the participation of *Anvisa* in the Pediatric medicines Regulators' Network (PmRN) ([@B48]), no similar initiative was taken by any Brazilian regulatory authority regarding pediatric drug development. Nevertheless, prioritization of license analysis of a new drug, further pharmaceutical form, new therapeutic indication, and new concentrations for children (fast track) can be requested ([@B11]).

Regarding other policies to ensure safer pharmacotherapy, Brazilian regulatory standards for manufacturers currently do not provide differentiated strategies for monitoring drugs used in children. *Anvisa* became a member of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) in 2016. There was a public consultation for update rules (in 2018) in which the Periodic Benefit-Risk Evaluation Report (PBRER) and the pharmacovigilance planning would meet the criteria adopted by ICH, concerning the information on the benefit-risk profile of drugs in special populations, such as children. Unfortunately, the new regulation is not yet published due to challenges in the resources required to complete the guidance *Anvisa* ([@B13]). Such challenges in the development and dissemination of territory-specific safety guidance can increase the risk associated with the use of children's medicines in middle-income countries like Brazil.

The percentage of drugs associated with any serious SADR level, which used OL, was 25% (range 21-67%) ([**Table 3**](#T3){ref-type="table"}). Children are especially vulnerable to SADRs due to the lack of data for this age group and the extensive use of OL and UL drugs ([@B16]). Reducing OL use in children could decrease the impact of SADRs, such as prolonged hospitalization, persistent disability, and death, as shown in [**Table 3**](#T3){ref-type="table"} (p\<0.05). In 2013, a prospective cohort study conducted in a pediatric hospital in the United Kingdom evaluating the impact of OL and UL prescribing on ADRs causing admissions to a pediatric hospital showed a 23% increase in ADR risk due to OL use ([@B5]).

Of the SADR reports which were associated with deaths, babies (0-1-year-old) (n=24; 32%) were the age group most implicated ([**Table 1**](#T1){ref-type="table"}). Neoplasms, respiratory, infectious and parasitic, related nervous or cardiovascular system diseases, and chromosomal abnormalities or congenital malformation stand out as causes of mortality and or morbidity in Brazilian children ([@B45]). Considering that most records were from hospitalized children, it was expected that serious ADRs in Brazil would involve babies and drugs with related indications, as shown in [**Table 4**](#T4){ref-type="table"}. Furthermore, drugs indicated for metabolism disorders (ICD class E) and infection diseases (ICD class J), as observed in [**Table 4**](#T4){ref-type="table"}, are well described in literature such as patterns of off-label prescribing in children ([@B31]; [@B23]). In severe clinical conditions, there is a complex assessment of the balance between risks and benefits, and, even if there is a higher chance of a fatal adverse event, the use of the drug might be the best medical decision. However, labels are a primary source of safety information from manufacturers for healthcare professionals and must be up to date with the frequency of ADRs in order to take precautionary and management measures in case of serious events ([@B8]).

There were only three reports classified as congenital anomalies. Although these are not drugs directly administered to children, damage to the fetus was suspected, making this information relevant for the pharmacotherapy monitoring and evaluation in special populations, including pregnant women. The pediatric disease burden in low-and middle-income countries is particularly affected by congenital anomalies, and the spontaneous notification of these events, as expected, was meager, which reinforces the demand for studies with better power to recognize these cases ([@B46]).

The present analysis described a high number of fatal events (67%) and were also associated with signals of disproportionate reporting (15%) ([**Table 5**](#T5){ref-type="table"}) not expressed in the product label.

Three drugs were suspected of eight or more fatal events: Miglustat, imipenem/cilastatin, and clofarabine. Of the suspected drugs associated with death, there was a high proportion of OL/UL use and specifically OK use, and, specifically the OL use (e.g., miglustat and imipenem/cilastatin) and UL use (e.g., clofarabine) associated with them ([**Table 4**](#T4){ref-type="table"}).

Disturbances such as diarrhea and flatulence are the most common adverse effects associated with miglustat therapy ([@B6]; [@B39]. In one fatal case, this event was present ([**Table 4**](#T4){ref-type="table"}). For imipenem/cilastatin, nausea and vomiting were also reported in the literature ([@B34]) and was present in cases of deaths. Most of the events reported in the literature for clofarabine, such as blood disorders (e.g., neutropenia) and respiratory disorders (e.g., respiratory distress), have been described ([@B27]; [@B36]) ([**Table 4**](#T4){ref-type="table"}).

Star et al. analyzed ([@B42]) pediatric individual case safety reports from Vigibase and founded 27 potential signals. After an in-depth assessment, they pointed out eight signals involving dextromethorphan (OL use), olanzapine (accidental overdose), atomoxetine (two signals), temozolomide, deferasirox, levetiracetam, and desloratadine. They used a data-driven predictive model that prioritized reporting a series of emergent signals by weighing disproportionate reporting patterns, completeness, recency, and geographic spread of individual case reporting and availability of case narratives.

Although it is one of Anvisa's goals, the Notivisa data analyzed in this study could not be sent to the Uppsala Monitoring Center, due to the incompatibility of notification systems, this study suggests the identification of new signals. However, we acknowledge that local practices, specific characteristics of the pediatric population, and pharmaceutical characteristics used in Brazil may have influenced our results.

We found 16 pairs involving serious events that need more assessment and follow-up. Imipenem/cilastatin and laronidase must be monitored for the risk of pneumonia and respiratory insufficiency, respectively. These pairs were reported as fatal events. A case report of imipenem/cilastatin-induced acute eosinophilic pneumonia in a 60-year-old woman ([@B21]) reinforces a suspected link of this ADR.

Disproportionality analysis in pharmacovigilance databases is an exploratory and reliable method to generate signals. Once a new disproportionality ratio for a drug has been observed, further studies can be conducted to confirm the signal ([@B32]).

Spontaneous reporting is considered an accessible and low-cost pharmacovigilance method that provides drug use assessment in real-life situations for large sample sizes ([@B38]). However, underreporting of adverse reactions makes it impossible to estimate the actual frequency of events. Another limitation of secondary database use is missing data, which is particularly important for causality assessment. Although notifiers were trained for a prior analysis of the suspected ADR, some of the necessary data had not been captured by *Anvisa* and cannot be undertaken retrospectively.

Conclusion {#s5}
==========

We found substantial SADRs reporting from the Brazilian database involving IV dosage forms and OL drug use in children. Imipenem and cilastatin, laronidase, clofarabine (unlicensed use), and miglustat (off label use) were suspected drugs related to deaths which were more frequently reported in the study period.

Moreover, the high number of signals of disproportionate reporting observed, mainly for anti-infectives, suggests that the safety profile of these medicines in children should be further investigated.

Finally, we recommend the dissemination and use of information from the periodic safety update reports for children, the development of pediatric formulations, and specific policy approval in Brazil following the examples of pediatric drug regulations in the US and Europe.
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